Sevelamer may not benefit heart in chronic kidney disease

04/19/2013 | MedPage Today (free registration)

Forty-week treatment with phosphate-binding agent sevelamer did not help left ventricular mass, LV function or arterial stiffness among patients with stage 3 chronic kidney disease compared with a placebo, according to a study in the Journal of the American Society of Nephrology. The drug reduced urinary phosphate and serum fibroblast growth factor-23 in a small group of adherent patients but failed to improve serum phosphate, vitamin D, klotho and cardiovascular outcomes.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX